Format

Send to

Choose Destination
Oncoimmunology. 2015 May 27;4(9):e1038017. eCollection 2015 Sep.

Adjuvant cellular immunotherapy in patients with resected primary non-small cell lung cancer.

Author information

1
Collaborative Innovation Center for Cancer Medicine; State Key Laboratory of Oncology in South China; Sun Yat-Sen University Cancer Center ; Guangzhou, China ; Department of Biotherapy; Sun Yat-Sen University Cancer Center ; Guangzhou, China.
2
Department of Biotherapy; Sun Yat-Sen University Cancer Center ; Guangzhou, China.
3
Department of Medical Oncology; Sun Yat-Sen University Cancer Center ; Guangzhou, China.
4
Department of Thoracic Surgery; Sun Yat-Sen University Cancer Center ; Guangzhou, China.

Abstract

Postoperative non-small cell lung cancer (NSCLC) patients require adjuvant therapy to improve their prognosis. In this study, we investigated the efficacy of a sequential combination of autologous cellular immunotherapy (CIT) and chemotherapy for postoperative NSCLC. This retrospective study included 120 postoperative NSCLC patients: 60 cases received only chemotherapy; 33 cases received chemotherapy and sequential CIT with cytokine-induced killer (CIK) cells; and 27 cases received chemotherapy and sequential CIT with alternate CIK and natural killer (NK) cells. Survival analysis showed significantly higher overall survival rates in the CIT group compared with the control group. Overall survival was higher in patients who received CIT with alternate CIK and NK cells than those who received treatment with only CIK cells. Multivariate analysis showed that adjuvant CIT was an independent prognostic factor for overall survival of patients with NSCLC. In subgroup analyses, adjuvant CIT significantly improved the overall survival of patients with less than 60 y old and positive lymph node. In conclusions, these data indicate that adjuvant CIT, especially with alternate application of CIK and NK cells, is an effective therapeutic approach to prolong survival of patients with NSCLC, particularly for patients ≤60 y old with positive lymph nodes.

KEYWORDS:

benefit; cellular immunotherapy; cytokine-induced killer cells; natural killer cells; non-small cell lung cancer

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center